BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 29614646)

  • 1. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.
    Teunissen CE; Chiu MJ; Yang CC; Yang SY; Scheltens P; Zetterberg H; Blennow K
    J Alzheimers Dis; 2018; 62(4):1857-1863. PubMed ID: 29614646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
    Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
    Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.
    Giedraitis V; Sundelöf J; Irizarry MC; Gårevik N; Hyman BT; Wahlund LO; Ingelsson M; Lannfelt L
    Neurosci Lett; 2007 Nov; 427(3):127-31. PubMed ID: 17936506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
    Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS
    Alzheimers Res Ther; 2016 Jun; 8():25. PubMed ID: 27358067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
    Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
    J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
    J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer's disease.
    Conti E; Gregori M; Radice I; Da Re F; Grana D; Re F; Salvati E; Masserini M; Ferrarese C; Zoia CP; Tremolizzo L
    Neurochem Int; 2017 Sep; 108():60-65. PubMed ID: 28238790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aβ1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease.
    Pérez-Grijalba V; Pesini P; Allué JA; Sarasa L; Montañés M; Lacosta AM; Casabona D; San-José I; Boada M; Tárraga L; Ruiz A; Sarasa M
    J Alzheimers Dis; 2015; 43(1):47-56. PubMed ID: 25061046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Fiorini M; Bongianni M; Benedetti MD; Monaco S; Zanusso G
    J Alzheimers Dis; 2018; 66(1):219-227. PubMed ID: 30282368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.
    Feinkohl I; Schipke CG; Kruppa J; Menne F; Winterer G; Pischon T; Peters O
    J Alzheimers Dis; 2020; 74(4):1285-1294. PubMed ID: 32176645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
    Vanderstichele H; Van Kerschaver E; Hesse C; Davidsson P; Buyse MA; Andreasen N; Minthon L; Wallin A; Blennow K; Vanmechelen E
    Amyloid; 2000 Dec; 7(4):245-58. PubMed ID: 11132093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model.
    Cho SM; Kim HV; Lee S; Kim HY; Kim W; Kim TS; Kim DJ; Kim Y
    Sci Rep; 2014 Oct; 4():6777. PubMed ID: 25345439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
    West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE
    Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
    Biscetti L; Salvadori N; Farotti L; Cataldi S; Eusebi P; Paciotti S; Parnetti L
    Clin Chim Acta; 2019 Jul; 494():71-73. PubMed ID: 30844364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.